Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Varga

Showing results (21-30 of 297) with videos related to

Pageof 30
Sort By:
Nature Reviews. Rheumatology|April 2, 2009
Transforming growth factor beta as a therapeutic target in systemic sclerosisJohn Varga, Boris Pasche
Current Rheumatology Reports|July 22, 2008
In perspective: murine models of sclerodermaMinghua Wu, John Varga
Nature Reviews. Rheumatology|February 19, 2014
Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets?John Varga, Monique Hinchcliff
Current Opinion in Rheumatology|October 6, 2007
Molecular pathways as novel therapeutic targets in systemic sclerosisMaria Trojanowska, John Varga
Current Opinion in Rheumatology|October 24, 2008
Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosisJohn Varga, Boris Pasche
Receptors & Clinical Investigation|August 25, 2023
Fibronectin signaling via toll-like receptprs: a novel paradigm for persistent fibrosis in sclerodermaSwati Bhattacharyya, John Varga
Current Rheumatology Reports|January 22, 2015
Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosisSwati Bhattacharyya, John Varga
Frontiers in Bioscience (Scholar Edition)|June 2, 2009
Transforming growth factor-beta in systemic sclerosis (scleroderma)John Varga, Michael L Whitfield
Nature Reviews. Rheumatology|February 6, 2025
Genome-wide mutagenesis reported in systemic sclerosisCarol M Artlett, John Varga
Current Opinion in Rheumatology|September 6, 2014
Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapyFlavia V Castelino, John Varga
Pageof 30

Showing results (21-30 of 297) with videos related to

Sort By:
Pageof 30
Nature Reviews. Rheumatology|April 2, 2009
Transforming growth factor beta as a therapeutic target in systemic sclerosisJohn Varga, Boris Pasche
Current Rheumatology Reports|July 22, 2008
In perspective: murine models of sclerodermaMinghua Wu, John Varga
Nature Reviews. Rheumatology|February 19, 2014
Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets?John Varga, Monique Hinchcliff
Current Opinion in Rheumatology|October 6, 2007
Molecular pathways as novel therapeutic targets in systemic sclerosisMaria Trojanowska, John Varga
Current Opinion in Rheumatology|October 24, 2008
Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosisJohn Varga, Boris Pasche
Receptors & Clinical Investigation|August 25, 2023
Fibronectin signaling via toll-like receptprs: a novel paradigm for persistent fibrosis in sclerodermaSwati Bhattacharyya, John Varga
Current Rheumatology Reports|January 22, 2015
Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosisSwati Bhattacharyya, John Varga
Frontiers in Bioscience (Scholar Edition)|June 2, 2009
Transforming growth factor-beta in systemic sclerosis (scleroderma)John Varga, Michael L Whitfield
Nature Reviews. Rheumatology|February 6, 2025
Genome-wide mutagenesis reported in systemic sclerosisCarol M Artlett, John Varga
Current Opinion in Rheumatology|September 6, 2014
Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapyFlavia V Castelino, John Varga
Pageof 30